Back to all Current clinical trials
Back to all Current clinical trials
Assessing the effectiveness of DB-1303 in the treatment of HER2-low breast cancer
The purpose of this trial is to assess the effectiveness of DB-1303 in the treatment of hormone receptor positive, HER2-low breast cancer, compared to standard of care.
What you need to know
Who can take part?
Inclusion:
Patient with advanced or metastatic breast cancer that is, HER2-low and Hormone Receptor positive.
Exclusion:
Patients with active cardiac disease or uncontrolled hypertension.
What is involved for me?
Visits occur for 1 day every week for 3 weeks. Then one day every 3 weeks.
Blood tests and vital signs at each visit
Regular tumor assessment via CT/ PET/MRI.
Physical exams, ECG and health questionnaires at the start of every treatment cycle.
Treatment will continue for as long as there is clinical benefit and no signification side effects.
